The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,002.00
Bid: 2,006.00
Ask: 2,008.00
Change: -10.00 (-0.50%)
Spread: 2.00 (0.10%)
Open: 2,014.00
High: 2,024.00
Low: 1,994.00
Prev. Close: 2,012.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma predicts generics revenue at top of guidance

Fri, 30th Apr 2021 07:38

(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.
The FTSE 100 drugs company said its injectables business was performing well with product launches and general demand in the US partly offsetting reduced demand for Covid-19 related products and the gradual return of elective surgeries.

The generics business had continued demand for certain Covid-19 related products and good performance from recent launches, more than offsetting stiffer competition on some products. Hikma has relaunched its generic version of Advair Diskus after getting approval in the US.

Hikma's Kloxxado naloxone nasal spray to treat opioid overdoses has received US approval. The company said annual generics revenue would be near the top of guidance for $770m-$810m with a core operating margin of about 20%.

The company said its branded business was doing well and, like injectables, would grow revenue by mid-single digits in 2021. Hikma stuck to its outlook for the full year.

Siggi Olafsson, Hikma's chief executive, said: "2021 is off to a good start with performance in line with our expectations. Our broad portfolio of essential medicines, strong commercial capabilities and over 30 new product launches across our markets have supported this progress. We expect to build on this momentum and are pleased to have recently resumed the launch of our high-quality, substitutable generic version of Advair Diskus. Our full-year outlook for the group is unchanged and we remain confident in our ability to deliver consistent long-term, sustainable growth."
More News
27 Sep 2021 09:31

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

LONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual

Read more
27 Sep 2021 09:28

UPDATE 2-Energy stocks, banks lift FTSE 100; Rolls-Royce top performer

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Rolls-Royce jumps on sales of Spain-based ITP, U.S. Air Force contract* Energy stocks track crude oil prices higher* Hikma Pharma gains o...

Read more
27 Sep 2021 08:50

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

LONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win

Read more
27 Sep 2021 08:16

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

TOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million

Read more
27 Sep 2021 07:49

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

LONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
27 Sep 2021 07:05

Hikma buys Custopharm for $375m

(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.

Read more
13 Sep 2021 16:09

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
2 Sep 2021 09:38

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

LONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC

Read more
27 Aug 2021 12:32

Hikma, Bio-Thera enter exclusive agreement for monoclonal antibody

(Sharecast News) - Bio-Thera Solutions and Hikma Pharmaceuticals have entered into a commercialisation and license agreement to commercialise a monoclonal antibody used for the treatment of Crohn's disease.

Read more
20 Aug 2021 09:46

LONDON BROKER RATINGS: Peel Hunt ups InterContinental Hotels to Hold

LONDON BROKER RATINGS: Peel Hunt ups InterContinental Hotels to Hold

Read more
20 Aug 2021 08:10

LONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons

LONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons

Read more
17 Aug 2021 09:46

UPDATE 2-Energy, healthcare stocks lift FTSE 100; BHP Group shines

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK employment closer to pre-pandemic levels* BHP Group jumps on strong results* PLUS500 gains on robust revenue forecasts* FTSE 100 up 0.3%...

Read more
12 Aug 2021 16:04

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
6 Aug 2021 17:06

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

LONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.